ホーム › トリプルネガティブ乳がん › ミネソタ州
ミネソタ州におけるトリプルネガティブ乳がんの臨床試験
ミネソタ州内の拠点で、トリプルネガティブ乳がんに関する17件の研究が参加者を募集しています。
ミネソタ州内の都市
公式研究テキスト（英語）
PRE-ISPY Phase I/II Oncology Platform Program
- University of Minnesota Masonic Cancer Center, Minneapolis
- Mayo Clinic Comprehensive Cancer Center, Rochester
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT05868226Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
- Mayo Clinic, Rochester
被験者募集中
30歳以上 · 女性 · 2026/09/25更新 · NCT02945579Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Mayo Clinic Rochester, Rochester
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/25更新 · NCT04981119Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Metro-Minnesota Community Clinical Oncology ( Site 0031), Saint Louis Park
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Allina Health Cancer Institute ( Site 0069), Minneapolis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06841354Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Mayo Clinic, Rochester
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT07340541First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
- Mayo Clinic, Rochester
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06657222Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Minnesota Oncology Hematology, PA, Maplewood
- Virginia Piper Cancer Center (Allina Health), Minneapolis
- University of Minnesota Medical Center, Fairview, Minneapolis
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT05633654A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Minneapolis
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07182149A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Minnesota Oncology Hematology, Maple Grove
- Local Institution - 0372, Minneapolis
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06926868Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Minnesota Oncology Hematology, Maplewood
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Mayo Clinic Rochester, Rochester
被験者募集中第1相
18歳〜100歳 · 全性別 · 2026/07/29更新 · NCT06562192A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Mayo Clinic - Rochester, Rochester
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/29更新 · NCT05377996Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- M Health Fairview University of Minnesota Medical Center - East Bank /ID# 276200, Minneapolis
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/23更新 · NCT05005403Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
- Mayo Clinic Rochester, Rochester
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/03更新 · NCT07311993I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- University of Minnesota, Minneapolis
- Mayo Clinic, Rochester
- Metro Minnesota Community Oncology Research Consortium, Hennepin County Medical Center, Saint Louis Park
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/06更新 · NCT01042379A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- Mayo Clinic, Rochester
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/09/09更新 · NCT06682793ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。